Lilly diabetes drug matches competitors' effectiveness

Back to TopCommentsE-mailPrintBookmark and Share

One of Eli Lilly and Co.’s experimental diabetes drugs was as effective at lowering blood sugar levels as the leading drug on the market, according to results of a study announced Tuesday by Lilly.

The Indianapolis-based drugmaker said its drug dulaglutide showed “non-inferiority” when tested against the strongest dose of Victoza, a best-selling drug for Type 2 diabetics made by Denmark-based Novo Nordisk A/S.

The study of 599 patients examined the effect on hemoglobin A1c scores, a measure of diabetes control.

Lilly said it would wait to disclose detailed results of its Phase 3 clinical trial of the two drugs until scientific meetings later this year. But the result is good news for Lilly, which is counting on dulaglutide and a few other drugs it plans to launch this year to rejuvenate its sales after the patent expiration in December of its top-selling drug, Cymbalta.

Before the latest study, Wall Street analysts predicted dulaglutide could achieve $1.5 billion a year in sales. Victoza generated $2.07 billion in 2013 sales for Novo Nordisk, according to data compiled by Bloomberg, and was the top seller in its class.

Dulaglutide has already proved itself superior to other diabetes drugs, including metformin, Byetta and Januvia, in clinicial studies announced last year.

But showing itself as good as Victoza should help Lilly secure better pricing from health insurers and state-run health plans.

“An approvable product is no longer the finish line for the industry. It’s a reimbursable product,” Mark Cziraky, vice president of research at HealthCore, a subsidiary of Indianapolis-based WellPoint Inc., told IBJ last year.

Dulaglutide is part of Lilly’s strategy to have a medication in every major class of therapy for diabetics. The company plans to use that portfolio to offer doctors a broad spectrum of treatments as well as to negotiate deals with health insurers and pharmacy managers.

“Options that allow patients to more easily use the treatment are, we believe, important,” said Sherry Martin, Lilly’s senior medical director, who oversaw the drug’s late-stage clinical trial.

Dulaglutide has been submitted to U.S. regulators for approval, with a decision expected by September. It would be the only once-a-week injection that doesn’t also require patients to prepare the dose, as AstraZeneca Plc’s Bydureon does.

In Lilly’s study, patients were given either 1.5 weekly milligrams of dulaglutide or 1.8 daily milligrams of Victoza, and their A1c scores were followed over 26 weeks. Lilly said that side effects were similar for both groups.

Both dulaglutide and Victoza are part of a class called GLP-1 receptor agonists. They tell the body to make more insulin when needed, as well as reduce the body’s sugar production.

About 25.8 million people in the U.S. have diabetes, or almost 8 percent of the population, according to the American Diabetes Association. The Type 2 form of the illness occurs when the body loses its natural ability to control sugar using insulin produced by the pancreas. It can be caused by obesity.


Post a comment to this story

We reserve the right to remove any post that we feel is obscene, profane, vulgar, racist, sexually explicit, abusive, or hateful.
You are legally responsible for what you post and your anonymity is not guaranteed.
Posts that insult, defame, threaten, harass or abuse other readers or people mentioned in IBJ editorial content are also subject to removal. Please respect the privacy of individuals and refrain from posting personal information.
No solicitations, spamming or advertisements are allowed. Readers may post links to other informational websites that are relevant to the topic at hand, but please do not link to objectionable material.
We may remove messages that are unrelated to the topic, encourage illegal activity, use all capital letters or are unreadable.

Messages that are flagged by readers as objectionable will be reviewed and may or may not be removed. Please do not flag a post simply because you disagree with it.

Sponsored by

facebook - twitter on Facebook & Twitter

Follow on TwitterFollow IBJ on Facebook:
Follow on TwitterFollow IBJ's Tweets on these topics:
Subscribe to IBJ
  1. A Tilted Kilt at a water park themed hotel? Who planned that one? I guess the Dad's need something to do while the kids are on the water slides.

  2. Don't come down on the fair for offering drinks. This is a craft and certainly one that belongs in agriculture due to ingredients. And for those worrying about how much you can drink. I'm sure it's more to do with liability than anything else. They don't want people suing for being over served. If you want a buzz, do a little pre-drinking before you go.

  3. I don't drink but go into this "controlled area" so my friend can drink. They have their 3 drink limit and then I give my friend my 3 drink limit. How is the fair going to control this very likely situation????

  4. I feel the conditions of the alcohol sales are a bit heavy handed, but you need to realize this is the first year in quite some time that beer & wine will be sold at the fair. They're starting off slowly to get a gauge on how it will perform this year - I would assume if everything goes fine that they relax some of the limits in the next year or couple of years. That said, I think requiring the consumption of alcohol to only occur in the beer tent is a bit much. That is going to be an awkward situation for those with minors - "Honey, I'm getting a beer... Ok, sure go ahead... Alright see you in just a min- half an hour."

  5. This might be an effort on the part of the State Fair Board to manage the risk until they get a better feel for it. However, the blanket notion that alcohol should not be served at "family oriented" events is perhaps an oversimplification. and not too realistic. For 15 years, I was a volunteer at the Indianapolis Air Show, which was as family oriented an event as it gets. We sold beer donated by Monarch Beverage Company and served by licensed and trained employees of United Package Liquors who were unpaid volunteers. And where did that money go? To central Indiana children's charities, including Riley Hospital for Children! It's all about managing the risk.